Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
Oncology Research
|
January 1, 1994
Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study
G Zaleskis, R L Ho, P Diegelman, et al.
International Journal of Clinical Practice
|
October 10, 2013
The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy
T Rhodes, J M Norquist, C McCrary Sisk, et al.
International Journal of Clinical Practice
|
June 4, 2010
Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia
S Shah, R Ceska, B Gil-Extremera, et al.
International Journal of Clinical Practice
|
January 27, 2009
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia
D Maccubbin, H E Bays, A G Olsson, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
Oncology Research
|
January 1, 1994
Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study
G Zaleskis, R L Ho, P Diegelman, et al.
International Journal of Clinical Practice
|
October 10, 2013
The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy
T Rhodes, J M Norquist, C McCrary Sisk, et al.
International Journal of Clinical Practice
|
June 4, 2010
Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia
S Shah, R Ceska, B Gil-Extremera, et al.
International Journal of Clinical Practice
|
January 27, 2009
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia
D Maccubbin, H E Bays, A G Olsson, et al.
Page
of 2